CAPR — Capricor Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.19bn
- $1.09bn
- $22.27m
Annual cashflow statement for Capricor Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.7 | -20 | -29 | -22.3 | -40.5 |
| Depreciation | |||||
| Non-Cash Items | 1.95 | 2.79 | 4.65 | 7.37 | 9.83 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.51 | 0.182 | 28.7 | -11.8 | -10.8 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -10.1 | -16.8 | 4.92 | -25.6 | -40 |
| Capital Expenditures | -0.548 | -1.2 | -3.36 | -2.05 | -1.54 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5.99 | 0 | -31.7 | 7.16 | -115 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 5.44 | -1.2 | -35.1 | 5.11 | -116 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 33.4 | 20.2 | 4.87 | 25.6 | 153 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 28.8 | 2.22 | -25.3 | 5.09 | -3.41 |